JNCE has a major deal with Celgene for $200 million. That said they still retain 60% of their future growth. This setup looks a lot like MYOK. The presence of out of the money call buying adds a little sizzle to an already good story.

In the last several days 4,000 Jun 15 $35 strike call contracts have been purchased for around $5. This indicates the buyers are looking for prices well north of $40 by June.

While they may not "need" funding , JNCE is taking the opportunity to raise funds with the stock price on the rise (smart management):

Jounce Therapeutics registers $250M mixed shelf offering

Mar. 8, 2018 4:51 PM ET|About: Jounce Therapeutics (JNCE)|By: Douglas W. House, SA News Editor 

Jounce Therapeutics (NASDAQ:JNCE) files a prospectus for a $250M mixed shelf offering. Net proceeds will be used for general corporate purposes.